Pharmiva Valuation

Is PHARM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PHARM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PHARM's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PHARM's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PHARM?

Key metric: As PHARM is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for PHARM. This is calculated by dividing PHARM's market cap by their current revenue.
What is PHARM's PS Ratio?
PS Ratio	2.3x
Sales	SEK 4.26m
Market Cap	SEK 9.73m

PHARM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.1x
Enterprise Value/EBITDA	-0.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does PHARM's PS Ratio compare to its peers?

The above table shows the PS ratio for PHARM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	9.5x
EEVIA Eevia Health Oyj	0.7x	n/a	SEK 16.0m
DANCAN DanCann Pharma	1x	n/a	DKK 8.6m
ZICC Ziccum	2.8x	n/a	SEK 15.9m
DBP B Double Bond Pharmaceutical International	33.5x	n/a	SEK 40.2m
PHARM Pharmiva	2.3x	n/a	SEK 9.7m

Price-To-Sales vs Peers: PHARM is good value based on its Price-To-Sales Ratio (2.3x) compared to the peer average (14.5x).

Price to Sales Ratio vs Industry

How does PHARM's PS Ratio compare vs other companies in the SE Pharmaceuticals Industry?

10 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	15.7x	32.9%
PHARM Pharmiva	2.3x	n/a	US$931.42k
SECARE Swedencare	2.9x	12.0%	US$647.75m
ORX Orexo	0.5x	11.3%	US$29.26m

10 Companies		Estimated Growth	Market Cap
Industry Avg.	15.7x	75.8%
PHARM Pharmiva	2.3x	n/a	US$931.42k

No more companies

Price-To-Sales vs Industry: PHARM is good value based on its Price-To-Sales Ratio (2.3x) compared to the Swedish Pharmaceuticals industry average (7.1x).

Price to Sales Ratio vs Fair Ratio

What is PHARM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PHARM PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	2.3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate PHARM's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

AstraZeneca

UK£156.0b

A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

AZN

UK£1,413.50

-1.8%

4.5%

Swedish Orphan Biovitrum

SEK 99.8b

An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.

SOBI

SEK 290.60

-12.4%

15.7%

PMD Device Solutions

SEK 33.2m

A digital medical device company, develops and sells respiratory monitoring solutions in Ireland.

PMDS

SEK 1.28

-14.7%

n/a